Robert Wolfe
Concepts (631)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Muscle Proteins | 83 | 2023 | 307 | 14.030 |
Why?
| Dietary Proteins | 48 | 2024 | 230 | 13.800 |
Why?
| Muscle, Skeletal | 104 | 2023 | 847 | 13.040 |
Why?
| Amino Acids, Essential | 45 | 2024 | 133 | 10.160 |
Why?
| Amino Acids | 56 | 2023 | 369 | 9.100 |
Why?
| Protein Biosynthesis | 28 | 2021 | 273 | 5.490 |
Why?
| Dietary Supplements | 32 | 2024 | 457 | 4.480 |
Why?
| Burns | 28 | 2022 | 170 | 4.450 |
Why?
| Nutritional Requirements | 15 | 2021 | 69 | 3.990 |
Why?
| Diet | 15 | 2024 | 598 | 3.500 |
Why?
| Phenylalanine | 47 | 2022 | 125 | 3.490 |
Why?
| Triglycerides | 18 | 2020 | 195 | 3.480 |
Why?
| Aging | 27 | 2020 | 784 | 3.450 |
Why?
| Sarcopenia | 10 | 2022 | 83 | 3.270 |
Why?
| Milk Proteins | 10 | 2016 | 77 | 3.180 |
Why?
| Isotopes | 6 | 2022 | 24 | 3.150 |
Why?
| Proteins | 15 | 2022 | 376 | 3.150 |
Why?
| Exercise | 26 | 2021 | 552 | 3.130 |
Why?
| Insulin | 37 | 2024 | 511 | 2.740 |
Why?
| Glucose | 18 | 2022 | 366 | 2.720 |
Why?
| Meals | 12 | 2022 | 62 | 2.640 |
Why?
| Insulin Resistance | 18 | 2024 | 300 | 2.400 |
Why?
| Leucine | 13 | 2023 | 113 | 2.250 |
Why?
| Bed Rest | 14 | 2020 | 39 | 2.230 |
Why?
| Anabolic Agents | 7 | 2019 | 35 | 2.200 |
Why?
| Body Composition | 26 | 2022 | 349 | 2.180 |
Why?
| Humans | 203 | 2024 | 54391 | 2.170 |
Why?
| Digestion | 5 | 2020 | 51 | 2.140 |
Why?
| Liver | 12 | 2021 | 1226 | 2.000 |
Why?
| Energy Intake | 10 | 2024 | 196 | 2.000 |
Why?
| Blood Glucose | 30 | 2020 | 489 | 1.930 |
Why?
| Kinetics | 28 | 2022 | 692 | 1.920 |
Why?
| Male | 138 | 2022 | 27347 | 1.830 |
Why?
| Skin | 10 | 2015 | 469 | 1.820 |
Why?
| Aged | 64 | 2024 | 10060 | 1.750 |
Why?
| Weight Loss | 6 | 2018 | 271 | 1.690 |
Why?
| Nutrition Policy | 7 | 2012 | 52 | 1.630 |
Why?
| Energy Metabolism | 18 | 2019 | 311 | 1.590 |
Why?
| Rabbits | 22 | 2015 | 425 | 1.590 |
Why?
| Palmitates | 7 | 2022 | 28 | 1.590 |
Why?
| Obesity | 13 | 2024 | 1203 | 1.570 |
Why?
| Feeding Behavior | 7 | 2020 | 200 | 1.540 |
Why?
| Resistance Training | 10 | 2022 | 102 | 1.470 |
Why?
| Muscle Strength | 12 | 2022 | 132 | 1.420 |
Why?
| Female | 108 | 2024 | 28471 | 1.410 |
Why?
| Lipid Metabolism | 7 | 2020 | 194 | 1.410 |
Why?
| Arginine | 9 | 2022 | 182 | 1.400 |
Why?
| Carbon Isotopes | 21 | 2017 | 71 | 1.390 |
Why?
| Hyperinsulinism | 6 | 2015 | 27 | 1.390 |
Why?
| Postprandial Period | 10 | 2021 | 79 | 1.330 |
Why?
| Adult | 76 | 2024 | 14207 | 1.320 |
Why?
| Wound Healing | 6 | 2008 | 228 | 1.310 |
Why?
| Animals | 49 | 2022 | 14409 | 1.300 |
Why?
| Leg | 19 | 2011 | 130 | 1.290 |
Why?
| Fatty Acids, Nonesterified | 10 | 2020 | 55 | 1.280 |
Why?
| Double-Blind Method | 16 | 2021 | 743 | 1.270 |
Why?
| Heart Failure | 3 | 2019 | 541 | 1.210 |
Why?
| Food, Formulated | 4 | 2019 | 44 | 1.120 |
Why?
| Wounds and Injuries | 6 | 2008 | 321 | 1.110 |
Why?
| Hypoglycemic Agents | 7 | 2013 | 177 | 1.100 |
Why?
| Dietary Carbohydrates | 10 | 2021 | 90 | 1.060 |
Why?
| Valerates | 3 | 2017 | 31 | 1.050 |
Why?
| Isotope Labeling | 4 | 2019 | 58 | 1.010 |
Why?
| Models, Biological | 11 | 2018 | 825 | 1.010 |
Why?
| Middle Aged | 56 | 2021 | 13082 | 1.000 |
Why?
| Cross-Over Studies | 13 | 2022 | 250 | 0.930 |
Why?
| Swine | 8 | 2019 | 430 | 0.930 |
Why?
| Overweight | 4 | 2018 | 240 | 0.920 |
Why?
| Pyruvic Acid | 3 | 2021 | 24 | 0.900 |
Why?
| Amino Acids, Branched-Chain | 3 | 2017 | 44 | 0.860 |
Why?
| Hyperglycemia | 6 | 2020 | 83 | 0.860 |
Why?
| Geriatric Assessment | 2 | 2021 | 126 | 0.830 |
Why?
| Nitric Oxide | 4 | 2015 | 298 | 0.810 |
Why?
| Whole Body Imaging | 2 | 2019 | 25 | 0.800 |
Why?
| Food Analysis | 1 | 2021 | 37 | 0.790 |
Why?
| Deuterium | 11 | 2019 | 41 | 0.790 |
Why?
| Critical Illness | 7 | 2016 | 344 | 0.790 |
Why?
| Gluconeogenesis | 1 | 2020 | 7 | 0.790 |
Why?
| Mitochondria, Muscle | 5 | 2020 | 46 | 0.780 |
Why?
| Lipoproteins, VLDL | 4 | 2024 | 16 | 0.780 |
Why?
| Lactic Acid | 2 | 2021 | 90 | 0.770 |
Why?
| Actinidia | 1 | 2020 | 7 | 0.770 |
Why?
| Glycolysis | 1 | 2021 | 73 | 0.760 |
Why?
| Kidney | 2 | 2021 | 822 | 0.750 |
Why?
| Hydrocortisone | 8 | 2020 | 124 | 0.750 |
Why?
| Muscular Atrophy | 4 | 2021 | 73 | 0.740 |
Why?
| Caloric Restriction | 3 | 2020 | 37 | 0.720 |
Why?
| Food, Fortified | 2 | 2021 | 33 | 0.720 |
Why?
| Muscle Contraction | 5 | 2019 | 111 | 0.710 |
Why?
| Aged, 80 and over | 12 | 2021 | 3431 | 0.700 |
Why?
| Metformin | 3 | 2005 | 66 | 0.700 |
Why?
| Renal Dialysis | 9 | 2015 | 193 | 0.700 |
Why?
| Elder Nutritional Physiological Phenomena | 2 | 2015 | 6 | 0.680 |
Why?
| Human Growth Hormone | 2 | 2017 | 51 | 0.680 |
Why?
| Nutritional Status | 6 | 2021 | 158 | 0.660 |
Why?
| Stress, Physiological | 4 | 2019 | 194 | 0.660 |
Why?
| Regional Blood Flow | 10 | 2015 | 121 | 0.650 |
Why?
| Muscle Cells | 4 | 2009 | 24 | 0.650 |
Why?
| DNA | 4 | 2007 | 581 | 0.650 |
Why?
| Adrenergic beta-Antagonists | 5 | 2006 | 105 | 0.650 |
Why?
| Beverages | 4 | 2019 | 83 | 0.640 |
Why?
| Sepsis | 6 | 2019 | 250 | 0.640 |
Why?
| Diabetes Mellitus | 2 | 2020 | 309 | 0.620 |
Why?
| Glucose Intolerance | 4 | 2020 | 28 | 0.610 |
Why?
| Critical Care | 2 | 2017 | 234 | 0.610 |
Why?
| Lipids | 7 | 2022 | 178 | 0.610 |
Why?
| Fenofibrate | 2 | 2007 | 16 | 0.600 |
Why?
| Hypolipidemic Agents | 2 | 2007 | 33 | 0.600 |
Why?
| Cardiovascular Diseases | 4 | 2021 | 476 | 0.600 |
Why?
| Eating | 9 | 2024 | 163 | 0.590 |
Why?
| Skin Transplantation | 3 | 2007 | 50 | 0.590 |
Why?
| Chromatography, High Pressure Liquid | 4 | 2007 | 377 | 0.590 |
Why?
| Spectrometry, Mass, Electrospray Ionization | 3 | 2005 | 67 | 0.570 |
Why?
| Young Adult | 15 | 2021 | 4318 | 0.560 |
Why?
| Time Factors | 18 | 2021 | 3210 | 0.560 |
Why?
| Weight Lifting | 3 | 2004 | 31 | 0.550 |
Why?
| Kidney Failure, Chronic | 7 | 2015 | 232 | 0.550 |
Why?
| Homeostasis | 3 | 2014 | 223 | 0.550 |
Why?
| Fatty Acids | 6 | 2013 | 175 | 0.550 |
Why?
| Proteolysis | 5 | 2020 | 102 | 0.540 |
Why?
| Cardiovascular Agents | 1 | 2015 | 60 | 0.520 |
Why?
| Citrulline | 1 | 2015 | 98 | 0.520 |
Why?
| Diet, Reducing | 1 | 2015 | 41 | 0.520 |
Why?
| Epidermis | 2 | 2006 | 31 | 0.510 |
Why?
| Nutritional Support | 1 | 2014 | 35 | 0.500 |
Why?
| Metabolomics | 1 | 2016 | 149 | 0.500 |
Why?
| Zinc | 2 | 2022 | 59 | 0.500 |
Why?
| Ileum | 3 | 2019 | 103 | 0.490 |
Why?
| Adipose Tissue | 4 | 2013 | 208 | 0.490 |
Why?
| Protein Stability | 2 | 2017 | 44 | 0.480 |
Why?
| Gas Chromatography-Mass Spectrometry | 4 | 2016 | 70 | 0.480 |
Why?
| Administration, Oral | 9 | 2009 | 461 | 0.480 |
Why?
| Up-Regulation | 1 | 2015 | 509 | 0.470 |
Why?
| Nitrogen Isotopes | 7 | 2022 | 36 | 0.460 |
Why?
| Muscle Development | 1 | 2013 | 25 | 0.450 |
Why?
| PPAR alpha | 3 | 2007 | 64 | 0.450 |
Why?
| Testosterone | 4 | 2007 | 119 | 0.450 |
Why?
| Radiopharmaceuticals | 1 | 2014 | 242 | 0.450 |
Why?
| Frail Elderly | 1 | 2012 | 32 | 0.440 |
Why?
| Infusions, Intravenous | 9 | 2021 | 231 | 0.440 |
Why?
| Body Mass Index | 13 | 2022 | 712 | 0.440 |
Why?
| Palmitoyl Coenzyme A | 4 | 2015 | 4 | 0.440 |
Why?
| Activities of Daily Living | 2 | 2014 | 204 | 0.430 |
Why?
| Adolescent | 23 | 2024 | 6900 | 0.430 |
Why?
| Biopsy | 9 | 2011 | 692 | 0.420 |
Why?
| Glycerol | 4 | 2009 | 22 | 0.420 |
Why?
| Fibroblasts | 2 | 2004 | 386 | 0.410 |
Why?
| Nutritional Physiological Phenomena | 4 | 2018 | 22 | 0.410 |
Why?
| Hormones | 5 | 2019 | 59 | 0.400 |
Why?
| Biological Availability | 3 | 2019 | 131 | 0.400 |
Why?
| Extracellular Fluid | 3 | 2006 | 19 | 0.390 |
Why?
| Phospholipids | 2 | 2020 | 63 | 0.390 |
Why?
| Threonine | 3 | 2022 | 17 | 0.390 |
Why?
| Arthroplasty, Replacement, Hip | 2 | 2021 | 249 | 0.380 |
Why?
| Metabolism | 5 | 2020 | 28 | 0.380 |
Why?
| Hospitalization | 3 | 2012 | 704 | 0.380 |
Why?
| Immobilization | 2 | 2007 | 14 | 0.370 |
Why?
| Nitrogen | 5 | 2022 | 78 | 0.370 |
Why?
| Heart Rate | 3 | 2007 | 358 | 0.370 |
Why?
| Cytokines | 4 | 2007 | 677 | 0.350 |
Why?
| Muscular Diseases | 3 | 2006 | 65 | 0.350 |
Why?
| Cardiac Output | 2 | 2006 | 50 | 0.350 |
Why?
| Biological Transport | 8 | 2013 | 195 | 0.340 |
Why?
| Propanolamines | 2 | 2006 | 12 | 0.340 |
Why?
| Lung Compliance | 2 | 2006 | 8 | 0.340 |
Why?
| Oxidation-Reduction | 7 | 2020 | 383 | 0.340 |
Why?
| Urea | 4 | 2022 | 83 | 0.340 |
Why?
| Hypertriglyceridemia | 1 | 2008 | 16 | 0.340 |
Why?
| Models, Animal | 4 | 2016 | 255 | 0.340 |
Why?
| Propranolol | 3 | 2006 | 78 | 0.330 |
Why?
| Diet, Carbohydrate-Restricted | 2 | 2018 | 9 | 0.330 |
Why?
| Area Under Curve | 6 | 2008 | 205 | 0.330 |
Why?
| Diet, Protein-Restricted | 3 | 2024 | 8 | 0.330 |
Why?
| Fibrinogen | 2 | 2005 | 37 | 0.330 |
Why?
| Protein Kinase C | 1 | 2008 | 65 | 0.320 |
Why?
| Hemoglobins | 2 | 2006 | 126 | 0.320 |
Why?
| Case-Control Studies | 7 | 2010 | 1229 | 0.320 |
Why?
| RNA, Transfer, Amino Acyl | 1 | 2007 | 1 | 0.320 |
Why?
| Intracellular Fluid | 2 | 2005 | 15 | 0.320 |
Why?
| Soft Tissue Injuries | 1 | 2008 | 22 | 0.320 |
Why?
| Protein Processing, Post-Translational | 1 | 2009 | 183 | 0.320 |
Why?
| Physical Endurance | 2 | 2005 | 49 | 0.310 |
Why?
| Reproducibility of Results | 6 | 2016 | 1301 | 0.310 |
Why?
| Absorptiometry, Photon | 5 | 2020 | 174 | 0.310 |
Why?
| Insulin, Long-Acting | 1 | 2007 | 1 | 0.300 |
Why?
| Acetates | 1 | 2007 | 50 | 0.300 |
Why?
| Herpesvirus 4, Human | 1 | 2007 | 39 | 0.300 |
Why?
| Intermittent Claudication | 1 | 2007 | 12 | 0.300 |
Why?
| Mitochondria | 2 | 2008 | 490 | 0.300 |
Why?
| Virus Activation | 1 | 2007 | 30 | 0.300 |
Why?
| Nutritive Value | 2 | 2017 | 39 | 0.300 |
Why?
| Pseudomonas Infections | 2 | 2017 | 54 | 0.300 |
Why?
| Peripheral Vascular Diseases | 1 | 2007 | 24 | 0.300 |
Why?
| Treatment Outcome | 14 | 2020 | 5612 | 0.290 |
Why?
| Acyl Coenzyme A | 2 | 2006 | 8 | 0.290 |
Why?
| Carbon Dioxide | 1 | 2007 | 103 | 0.290 |
Why?
| Child | 19 | 2022 | 7368 | 0.290 |
Why?
| Malnutrition | 3 | 2021 | 82 | 0.290 |
Why?
| Muscles | 2 | 2006 | 114 | 0.290 |
Why?
| Creatine | 2 | 2016 | 38 | 0.290 |
Why?
| Dermis | 2 | 2004 | 20 | 0.290 |
Why?
| Body Weight | 6 | 2013 | 578 | 0.290 |
Why?
| Mafenide | 1 | 2006 | 1 | 0.290 |
Why?
| Hemodynamics | 2 | 2017 | 291 | 0.280 |
Why?
| Adrenergic beta-1 Receptor Antagonists | 1 | 2006 | 6 | 0.280 |
Why?
| Carnitine | 2 | 2010 | 86 | 0.280 |
Why?
| Living Donors | 1 | 2006 | 25 | 0.280 |
Why?
| Military Personnel | 2 | 2019 | 174 | 0.270 |
Why?
| Blood Flow Velocity | 5 | 2007 | 114 | 0.270 |
Why?
| Hormone Replacement Therapy | 1 | 2005 | 27 | 0.270 |
Why?
| Fatty Liver | 2 | 2024 | 129 | 0.270 |
Why?
| Shock, Hemorrhagic | 1 | 2005 | 10 | 0.270 |
Why?
| Mitochondrial Proteins | 3 | 2022 | 121 | 0.260 |
Why?
| Walkers | 1 | 2004 | 2 | 0.260 |
Why?
| Brain Injuries | 1 | 2007 | 184 | 0.260 |
Why?
| Models, Theoretical | 2 | 2016 | 184 | 0.260 |
Why?
| Blood Coagulation | 1 | 2005 | 69 | 0.260 |
Why?
| Alanine | 2 | 2004 | 44 | 0.250 |
Why?
| Caseins | 1 | 2004 | 73 | 0.250 |
Why?
| Glucose Clamp Technique | 5 | 2009 | 19 | 0.250 |
Why?
| Malonyl Coenzyme A | 2 | 2010 | 9 | 0.250 |
Why?
| Hyperandrogenism | 1 | 2024 | 1 | 0.250 |
Why?
| Exercise Tolerance | 1 | 2004 | 48 | 0.250 |
Why?
| Polycystic Ovary Syndrome | 1 | 2024 | 11 | 0.240 |
Why?
| Dose-Response Relationship, Drug | 5 | 2009 | 1476 | 0.240 |
Why?
| Physical Exertion | 1 | 2004 | 67 | 0.240 |
Why?
| Developed Countries | 1 | 2024 | 12 | 0.240 |
Why?
| Metabolic Clearance Rate | 5 | 2019 | 75 | 0.240 |
Why?
| Egg Proteins | 2 | 2021 | 19 | 0.240 |
Why?
| Inulin | 1 | 2003 | 7 | 0.240 |
Why?
| Dietary Fats | 2 | 2017 | 142 | 0.240 |
Why?
| Meat | 3 | 2021 | 59 | 0.240 |
Why?
| Cell Division | 4 | 2006 | 330 | 0.240 |
Why?
| Child, Preschool | 10 | 2022 | 4158 | 0.240 |
Why?
| Injections, Intravenous | 2 | 2014 | 148 | 0.230 |
Why?
| Accidental Falls | 1 | 2004 | 98 | 0.230 |
Why?
| Disabled Persons | 1 | 2004 | 105 | 0.230 |
Why?
| Eukaryotic Initiation Factor-2B | 1 | 2003 | 4 | 0.230 |
Why?
| Nutrition Surveys | 1 | 2024 | 122 | 0.230 |
Why?
| Algorithms | 5 | 2015 | 697 | 0.230 |
Why?
| Valine | 1 | 2003 | 54 | 0.230 |
Why?
| Disease Models, Animal | 3 | 2019 | 1647 | 0.230 |
Why?
| Carnitine O-Palmitoyltransferase | 1 | 2002 | 12 | 0.220 |
Why?
| Carbohydrate Metabolism | 2 | 2019 | 31 | 0.220 |
Why?
| Pseudomonas aeruginosa | 3 | 2019 | 86 | 0.220 |
Why?
| Reference Values | 6 | 2017 | 354 | 0.220 |
Why?
| Vasodilator Agents | 1 | 2003 | 111 | 0.220 |
Why?
| Splanchnic Circulation | 1 | 2002 | 43 | 0.220 |
Why?
| Polymers | 1 | 2022 | 44 | 0.220 |
Why?
| Pulmonary Surfactants | 1 | 2002 | 18 | 0.220 |
Why?
| Tyrosine | 4 | 2022 | 137 | 0.220 |
Why?
| Glutamine | 1 | 2003 | 168 | 0.210 |
Why?
| Alaska | 2 | 2020 | 29 | 0.210 |
Why?
| GTP-Binding Proteins | 1 | 2022 | 94 | 0.210 |
Why?
| Reindeer | 1 | 2021 | 4 | 0.210 |
Why?
| Calorimetry, Indirect | 4 | 2006 | 29 | 0.210 |
Why?
| Myostatin | 1 | 2021 | 10 | 0.200 |
Why?
| Mitochondrial Dynamics | 2 | 2020 | 22 | 0.200 |
Why?
| Age Factors | 6 | 2017 | 1199 | 0.200 |
Why?
| Fasting | 4 | 2020 | 76 | 0.200 |
Why?
| Proteolipids | 1 | 2021 | 9 | 0.200 |
Why?
| Autophagy | 2 | 2020 | 202 | 0.200 |
Why?
| Lysine | 2 | 2017 | 102 | 0.200 |
Why?
| Glycogenolysis | 1 | 2020 | 9 | 0.200 |
Why?
| Leptin | 1 | 2022 | 154 | 0.200 |
Why?
| Plant Proteins | 1 | 2021 | 73 | 0.190 |
Why?
| Neoplasms | 1 | 2011 | 1322 | 0.190 |
Why?
| Physical Conditioning, Animal | 1 | 2021 | 59 | 0.190 |
Why?
| Injections, Intramuscular | 2 | 2011 | 50 | 0.190 |
Why?
| Hyperphagia | 1 | 2020 | 11 | 0.190 |
Why?
| Random Allocation | 2 | 2015 | 312 | 0.190 |
Why?
| Severity of Illness Index | 4 | 2017 | 1082 | 0.190 |
Why?
| Palmitic Acid | 4 | 2005 | 25 | 0.190 |
Why?
| Postoperative Care | 1 | 2021 | 121 | 0.190 |
Why?
| Health Status | 2 | 2016 | 368 | 0.190 |
Why?
| Prospective Studies | 5 | 2017 | 2606 | 0.190 |
Why?
| Fatty Acids, Omega-3 | 1 | 2020 | 29 | 0.190 |
Why?
| Breast Feeding | 1 | 2022 | 191 | 0.190 |
Why?
| Hypoglycemia | 1 | 2020 | 61 | 0.190 |
Why?
| Femoral Artery | 3 | 2007 | 122 | 0.180 |
Why?
| Fatty Liver, Alcoholic | 1 | 2020 | 8 | 0.180 |
Why?
| Analysis of Variance | 6 | 2009 | 634 | 0.180 |
Why?
| Preoperative Care | 1 | 2021 | 184 | 0.180 |
Why?
| Glycine | 3 | 2004 | 70 | 0.180 |
Why?
| RNA, Messenger | 2 | 2022 | 1203 | 0.180 |
Why?
| Health | 2 | 2012 | 28 | 0.180 |
Why?
| Mouth | 1 | 2019 | 35 | 0.180 |
Why?
| Hindlimb | 3 | 2008 | 25 | 0.180 |
Why?
| Molecular Probe Techniques | 1 | 2019 | 9 | 0.180 |
Why?
| Carcinoma, Hepatocellular | 1 | 2022 | 203 | 0.170 |
Why?
| Military Medicine | 1 | 2019 | 21 | 0.170 |
Why?
| Fruit | 1 | 2020 | 144 | 0.170 |
Why?
| Evaluation Studies as Topic | 1 | 2019 | 107 | 0.170 |
Why?
| Altitude Sickness | 2 | 2012 | 8 | 0.170 |
Why?
| Palmitoylcarnitine | 2 | 2011 | 8 | 0.170 |
Why?
| United States | 5 | 2024 | 5208 | 0.170 |
Why?
| Water | 1 | 2019 | 103 | 0.170 |
Why?
| Intestinal Absorption | 1 | 2019 | 60 | 0.170 |
Why?
| Proteome | 1 | 2020 | 178 | 0.170 |
Why?
| Jejunum | 1 | 2019 | 56 | 0.170 |
Why?
| Hypoalbuminemia | 1 | 2018 | 5 | 0.170 |
Why?
| Basal Metabolism | 3 | 2020 | 36 | 0.170 |
Why?
| Lung | 1 | 2002 | 508 | 0.170 |
Why?
| Diet, High-Fat | 1 | 2020 | 216 | 0.160 |
Why?
| Occupational Diseases | 1 | 2019 | 93 | 0.160 |
Why?
| Cholesterol | 3 | 2013 | 155 | 0.160 |
Why?
| Liver Neoplasms | 1 | 2022 | 352 | 0.160 |
Why?
| Oxandrolone | 2 | 2011 | 10 | 0.160 |
Why?
| Breakfast | 1 | 2017 | 16 | 0.160 |
Why?
| Lower Extremity | 2 | 2009 | 103 | 0.160 |
Why?
| Inflammation | 4 | 2018 | 678 | 0.150 |
Why?
| Alcohol Drinking | 1 | 2020 | 259 | 0.150 |
Why?
| Injections, Intradermal | 2 | 2007 | 15 | 0.150 |
Why?
| Oxygen Consumption | 6 | 2019 | 223 | 0.150 |
Why?
| Intestinal Mucosa | 1 | 2019 | 259 | 0.150 |
Why?
| Circadian Rhythm | 1 | 2017 | 85 | 0.150 |
Why?
| Gastrointestinal Tract | 1 | 2018 | 136 | 0.150 |
Why?
| Quadriceps Muscle | 1 | 2017 | 49 | 0.150 |
Why?
| Hypertension, Pulmonary | 2 | 2012 | 126 | 0.150 |
Why?
| Sleep Apnea, Obstructive | 1 | 2017 | 65 | 0.150 |
Why?
| Endpoint Determination | 1 | 2016 | 30 | 0.140 |
Why?
| Nutrition Assessment | 1 | 2017 | 80 | 0.140 |
Why?
| Food Quality | 1 | 2016 | 1 | 0.140 |
Why?
| Egg Proteins, Dietary | 1 | 2016 | 2 | 0.140 |
Why?
| Physical Fitness | 2 | 2014 | 69 | 0.140 |
Why?
| Athletic Performance | 1 | 2016 | 46 | 0.140 |
Why?
| Chromatography, Liquid | 2 | 2008 | 243 | 0.140 |
Why?
| Rest | 2 | 2007 | 68 | 0.140 |
Why?
| Tissue Donors | 2 | 2007 | 112 | 0.140 |
Why?
| Hyperemia | 1 | 2015 | 23 | 0.140 |
Why?
| Constriction | 2 | 2007 | 9 | 0.130 |
Why?
| Forearm | 1 | 2015 | 41 | 0.130 |
Why?
| Magnetic Resonance Spectroscopy | 2 | 2008 | 255 | 0.130 |
Why?
| Enteral Nutrition | 3 | 2006 | 136 | 0.130 |
Why?
| Chronic Disease | 4 | 2017 | 614 | 0.130 |
Why?
| Microdialysis | 2 | 2005 | 21 | 0.130 |
Why?
| Waist Circumference | 1 | 2015 | 20 | 0.130 |
Why?
| Capillaries | 2 | 2007 | 58 | 0.130 |
Why?
| Hand Strength | 1 | 2015 | 32 | 0.130 |
Why?
| Cross-Sectional Studies | 3 | 2008 | 1696 | 0.120 |
Why?
| Femoral Vein | 2 | 2005 | 45 | 0.120 |
Why?
| Radioactive Tracers | 2 | 2019 | 8 | 0.120 |
Why?
| NF-kappa B | 2 | 2007 | 336 | 0.120 |
Why?
| Proline | 2 | 2004 | 31 | 0.120 |
Why?
| Weight Gain | 2 | 2022 | 244 | 0.120 |
Why?
| Exercise Test | 3 | 2019 | 151 | 0.120 |
Why?
| Pulmonary Edema | 2 | 2004 | 17 | 0.120 |
Why?
| Logistic Models | 2 | 2015 | 991 | 0.120 |
Why?
| Statistics, Nonparametric | 2 | 2011 | 232 | 0.120 |
Why?
| Endothelium, Vascular | 1 | 2015 | 288 | 0.120 |
Why?
| Walking | 1 | 2014 | 110 | 0.120 |
Why?
| Motor Activity | 3 | 2010 | 249 | 0.120 |
Why?
| Musculoskeletal Physiological Phenomena | 1 | 2013 | 4 | 0.120 |
Why?
| Extremities | 1 | 2013 | 27 | 0.110 |
Why?
| Carbohydrates | 2 | 2019 | 64 | 0.110 |
Why?
| Arginase | 1 | 2012 | 39 | 0.110 |
Why?
| Risk Assessment | 4 | 2017 | 1362 | 0.110 |
Why?
| Oxygen | 2 | 2006 | 361 | 0.110 |
Why?
| Altitude | 1 | 2012 | 17 | 0.110 |
Why?
| Cystic Fibrosis | 2 | 2013 | 157 | 0.110 |
Why?
| Metabolic Diseases | 1 | 2012 | 44 | 0.110 |
Why?
| Follow-Up Studies | 4 | 2017 | 2390 | 0.100 |
Why?
| Nitric Oxide Synthase | 2 | 2012 | 102 | 0.100 |
Why?
| Guidelines as Topic | 1 | 2012 | 125 | 0.100 |
Why?
| Organ Size | 1 | 2012 | 237 | 0.100 |
Why?
| Healthcare Disparities | 1 | 2015 | 269 | 0.100 |
Why?
| Cattle | 2 | 2022 | 225 | 0.100 |
Why?
| Glucose Tolerance Test | 3 | 2010 | 67 | 0.100 |
Why?
| Evidence-Based Medicine | 1 | 2012 | 276 | 0.100 |
Why?
| Cell Line | 2 | 2004 | 1152 | 0.100 |
Why?
| Parenteral Nutrition | 2 | 2016 | 24 | 0.090 |
Why?
| Pulmonary Artery | 1 | 2012 | 152 | 0.090 |
Why?
| Breath Tests | 2 | 2007 | 44 | 0.090 |
Why?
| Cushing Syndrome | 1 | 2009 | 13 | 0.090 |
Why?
| Texas | 2 | 2007 | 160 | 0.090 |
Why?
| Randomized Controlled Trials as Topic | 3 | 2022 | 594 | 0.090 |
Why?
| Antiphospholipid Syndrome | 1 | 2009 | 7 | 0.090 |
Why?
| Cholesterol, VLDL | 1 | 2008 | 3 | 0.090 |
Why?
| Intracellular Signaling Peptides and Proteins | 1 | 2010 | 151 | 0.090 |
Why?
| Body Surface Area | 2 | 2006 | 25 | 0.090 |
Why?
| Polysomnography | 2 | 2020 | 71 | 0.090 |
Why?
| Blood Pressure | 2 | 2017 | 587 | 0.080 |
Why?
| Institutionalization | 1 | 2008 | 11 | 0.080 |
Why?
| Cachexia | 1 | 2008 | 24 | 0.080 |
Why?
| Satiation | 1 | 2008 | 8 | 0.080 |
Why?
| Muscle Strength Dynamometer | 1 | 2008 | 12 | 0.080 |
Why?
| Kidney Function Tests | 1 | 2008 | 59 | 0.080 |
Why?
| Fontan Procedure | 1 | 2009 | 56 | 0.080 |
Why?
| Mice | 4 | 2022 | 6428 | 0.080 |
Why?
| Parenteral Nutrition Solutions | 2 | 2004 | 8 | 0.080 |
Why?
| Solutions | 2 | 2004 | 29 | 0.080 |
Why?
| Sodium Bicarbonate | 1 | 2007 | 9 | 0.080 |
Why?
| Citric Acid Cycle | 1 | 2007 | 20 | 0.080 |
Why?
| Ketoconazole | 1 | 2007 | 17 | 0.080 |
Why?
| Linear Models | 2 | 2009 | 308 | 0.080 |
Why?
| RNA, Transfer | 1 | 2007 | 25 | 0.080 |
Why?
| Electrolytes | 2 | 2004 | 25 | 0.080 |
Why?
| Space Simulation | 1 | 2007 | 2 | 0.080 |
Why?
| Sleep | 2 | 2020 | 188 | 0.080 |
Why?
| Hypoplastic Left Heart Syndrome | 1 | 2009 | 97 | 0.080 |
Why?
| Gene Expression Regulation | 4 | 2010 | 1063 | 0.080 |
Why?
| Tandem Mass Spectrometry | 1 | 2008 | 248 | 0.080 |
Why?
| Virus Latency | 1 | 2007 | 46 | 0.080 |
Why?
| Adenosine Triphosphate | 1 | 2008 | 242 | 0.070 |
Why?
| Saliva | 1 | 2007 | 63 | 0.070 |
Why?
| Gait | 1 | 2008 | 98 | 0.070 |
Why?
| Acute Disease | 2 | 2019 | 403 | 0.070 |
Why?
| Trauma Severity Indices | 1 | 2007 | 57 | 0.070 |
Why?
| Insulin-Like Growth Factor I | 1 | 2007 | 137 | 0.070 |
Why?
| Cell Compartmentation | 1 | 2006 | 17 | 0.070 |
Why?
| Siloxanes | 1 | 2006 | 2 | 0.070 |
Why?
| Styrenes | 1 | 2006 | 3 | 0.070 |
Why?
| Sex Factors | 2 | 2020 | 766 | 0.070 |
Why?
| RNA | 1 | 2007 | 202 | 0.070 |
Why?
| Occlusive Dressings | 1 | 2006 | 7 | 0.070 |
Why?
| APACHE | 1 | 2006 | 24 | 0.070 |
Why?
| Bandages | 1 | 2006 | 22 | 0.070 |
Why?
| Administration, Topical | 1 | 2006 | 71 | 0.070 |
Why?
| Osmolar Concentration | 2 | 2003 | 83 | 0.070 |
Why?
| Risk Factors | 4 | 2019 | 3937 | 0.070 |
Why?
| Hepatomegaly | 1 | 2006 | 10 | 0.070 |
Why?
| Anti-Infective Agents, Local | 1 | 2006 | 24 | 0.070 |
Why?
| Dermatologic Surgical Procedures | 1 | 2006 | 38 | 0.070 |
Why?
| Methods | 1 | 2005 | 66 | 0.070 |
Why?
| Carbohydrate Sequence | 1 | 2005 | 21 | 0.070 |
Why?
| Creatinine | 1 | 2006 | 169 | 0.070 |
Why?
| Injury Severity Score | 1 | 2006 | 178 | 0.070 |
Why?
| Reference Standards | 1 | 2005 | 63 | 0.070 |
Why?
| Anti-Inflammatory Agents | 1 | 2007 | 175 | 0.070 |
Why?
| Infusions, Intra-Arterial | 1 | 2005 | 18 | 0.070 |
Why?
| Fibrinolysis | 1 | 2005 | 8 | 0.070 |
Why?
| Pressure Ulcer | 1 | 2005 | 18 | 0.070 |
Why?
| Blood Coagulation Tests | 1 | 2005 | 23 | 0.070 |
Why?
| Life Style | 1 | 2006 | 156 | 0.070 |
Why?
| Body Water | 1 | 2005 | 34 | 0.070 |
Why?
| Hematocrit | 1 | 2005 | 51 | 0.070 |
Why?
| Arteries | 2 | 2004 | 101 | 0.070 |
Why?
| Milk | 1 | 2006 | 94 | 0.070 |
Why?
| Fluorocarbons | 1 | 2005 | 52 | 0.070 |
Why?
| Ecchymosis | 1 | 2004 | 8 | 0.060 |
Why?
| Stress, Psychological | 1 | 2007 | 270 | 0.060 |
Why?
| Placebos | 1 | 2004 | 90 | 0.060 |
Why?
| Blood Specimen Collection | 1 | 2004 | 39 | 0.060 |
Why?
| Practice Guidelines as Topic | 1 | 2008 | 489 | 0.060 |
Why?
| Radioisotope Dilution Technique | 1 | 2004 | 12 | 0.060 |
Why?
| Myocardial Infarction | 1 | 2009 | 423 | 0.060 |
Why?
| Biological Transport, Active | 1 | 2004 | 35 | 0.060 |
Why?
| Osteoporosis | 1 | 2006 | 164 | 0.060 |
Why?
| Muscle Fatigue | 1 | 2004 | 12 | 0.060 |
Why?
| Hematoma | 1 | 2004 | 63 | 0.060 |
Why?
| Signal Transduction | 3 | 2020 | 1752 | 0.060 |
Why?
| Culture Media | 1 | 2004 | 100 | 0.060 |
Why?
| Interleukin-18 | 1 | 2024 | 27 | 0.060 |
Why?
| Health Care Rationing | 1 | 2004 | 12 | 0.060 |
Why?
| Catheterization | 1 | 2004 | 108 | 0.060 |
Why?
| Locomotion | 1 | 2004 | 83 | 0.060 |
Why?
| Iontophoresis | 1 | 2003 | 15 | 0.060 |
Why?
| Biopsy, Needle | 1 | 2004 | 195 | 0.060 |
Why?
| Respiratory Function Tests | 1 | 2004 | 98 | 0.060 |
Why?
| Physical Education and Training | 1 | 2004 | 27 | 0.060 |
Why?
| Albumins | 1 | 2004 | 39 | 0.060 |
Why?
| Pilocarpine | 1 | 2003 | 23 | 0.060 |
Why?
| Amino Acid Sequence | 1 | 2005 | 767 | 0.060 |
Why?
| Amino Acid Transport Systems | 1 | 2003 | 6 | 0.060 |
Why?
| Waiting Lists | 1 | 2004 | 49 | 0.060 |
Why?
| Adaptation, Physiological | 1 | 2004 | 103 | 0.060 |
Why?
| Molecular Sequence Data | 1 | 2005 | 980 | 0.060 |
Why?
| RNA, Ribosomal, 16S | 1 | 2024 | 116 | 0.060 |
Why?
| Glutamic Acid | 1 | 2004 | 111 | 0.060 |
Why?
| Equipment Design | 1 | 2004 | 318 | 0.060 |
Why?
| Injections, Intra-Arterial | 1 | 2003 | 13 | 0.060 |
Why?
| Nitric Oxide Donors | 1 | 2003 | 12 | 0.060 |
Why?
| Nitroprusside | 1 | 2003 | 12 | 0.060 |
Why?
| Cell Count | 1 | 2004 | 181 | 0.060 |
Why?
| Cough | 1 | 2003 | 55 | 0.060 |
Why?
| Obesity, Morbid | 1 | 2004 | 88 | 0.060 |
Why?
| Tissue and Organ Procurement | 1 | 2004 | 40 | 0.060 |
Why?
| Time | 1 | 2003 | 36 | 0.060 |
Why?
| Regression Analysis | 1 | 2004 | 445 | 0.060 |
Why?
| Carbazoles | 1 | 2003 | 16 | 0.060 |
Why?
| Blood Circulation | 1 | 2003 | 20 | 0.060 |
Why?
| Hydroxyproline | 1 | 2003 | 20 | 0.060 |
Why?
| Ventricular Dysfunction | 1 | 2003 | 10 | 0.060 |
Why?
| Indocyanine Green | 1 | 2003 | 39 | 0.060 |
Why?
| Body Constitution | 1 | 2002 | 12 | 0.060 |
Why?
| Coloring Agents | 1 | 2003 | 84 | 0.060 |
Why?
| Computer Simulation | 1 | 2004 | 332 | 0.060 |
Why?
| Ovarian Neoplasms | 1 | 2007 | 474 | 0.060 |
Why?
| Transposition of Great Vessels | 1 | 2003 | 24 | 0.060 |
Why?
| Drug Combinations | 1 | 2003 | 128 | 0.060 |
Why?
| Fish Oils | 1 | 2002 | 9 | 0.050 |
Why?
| Linoleic Acid | 1 | 2002 | 15 | 0.050 |
Why?
| Fat Emulsions, Intravenous | 1 | 2002 | 11 | 0.050 |
Why?
| Ear | 1 | 2002 | 20 | 0.050 |
Why?
| Phosphatidylcholines | 1 | 2002 | 33 | 0.050 |
Why?
| Blood Proteins | 1 | 2023 | 100 | 0.050 |
Why?
| Leukocyte Count | 1 | 2002 | 77 | 0.050 |
Why?
| Microspheres | 1 | 2002 | 34 | 0.050 |
Why?
| Endotoxins | 1 | 2002 | 37 | 0.050 |
Why?
| Cell Membrane | 1 | 2003 | 279 | 0.050 |
Why?
| Lactates | 1 | 2022 | 34 | 0.050 |
Why?
| Communicable Disease Control | 1 | 2022 | 39 | 0.050 |
Why?
| Carotid Arteries | 1 | 2002 | 82 | 0.050 |
Why?
| Ribosomal Proteins | 1 | 2022 | 32 | 0.050 |
Why?
| Drug Synergism | 1 | 2002 | 171 | 0.050 |
Why?
| Sensitivity and Specificity | 1 | 2004 | 922 | 0.050 |
Why?
| Kidney Diseases | 1 | 2005 | 293 | 0.050 |
Why?
| Liver Transplantation | 1 | 2004 | 159 | 0.050 |
Why?
| Thinness | 2 | 2016 | 57 | 0.050 |
Why?
| Neutrophils | 1 | 2002 | 154 | 0.050 |
Why?
| Cell Cycle Proteins | 1 | 2022 | 198 | 0.050 |
Why?
| Tumor Microenvironment | 1 | 2022 | 210 | 0.050 |
Why?
| Food | 1 | 2020 | 69 | 0.050 |
Why?
| Ceramides | 1 | 2020 | 32 | 0.050 |
Why?
| Gene Expression | 1 | 2003 | 664 | 0.050 |
Why?
| Orthopedic Procedures | 1 | 2021 | 82 | 0.050 |
Why?
| Dexamethasone | 1 | 2022 | 435 | 0.050 |
Why?
| Protein Kinases | 1 | 2020 | 88 | 0.040 |
Why?
| Proto-Oncogene Proteins c-akt | 1 | 2020 | 176 | 0.040 |
Why?
| T-Lymphocytes | 1 | 2022 | 374 | 0.040 |
Why?
| Occupational Health | 1 | 2019 | 74 | 0.040 |
Why?
| Capillary Permeability | 1 | 2018 | 40 | 0.040 |
Why?
| Rats, Zucker | 2 | 2010 | 74 | 0.040 |
Why?
| Diabetes Mellitus, Type 2 | 1 | 2004 | 486 | 0.040 |
Why?
| Body Weights and Measures | 1 | 2017 | 20 | 0.040 |
Why?
| Hunger | 1 | 2017 | 23 | 0.040 |
Why?
| Artifacts | 1 | 2018 | 61 | 0.040 |
Why?
| Animal Structures | 1 | 2017 | 2 | 0.040 |
Why?
| Clinical Chemistry Tests | 1 | 2017 | 3 | 0.040 |
Why?
| Blood Gas Analysis | 1 | 2017 | 32 | 0.040 |
Why?
| Withholding Treatment | 1 | 2017 | 21 | 0.040 |
Why?
| Apoptosis | 1 | 2003 | 1302 | 0.040 |
Why?
| Indicator Dilution Techniques | 1 | 2017 | 11 | 0.040 |
Why?
| Venae Cavae | 1 | 2017 | 9 | 0.040 |
Why?
| Crosses, Genetic | 1 | 2017 | 31 | 0.040 |
Why?
| Sus scrofa | 1 | 2017 | 39 | 0.040 |
Why?
| Inflammation Mediators | 1 | 2017 | 128 | 0.040 |
Why?
| Pilot Projects | 1 | 2020 | 807 | 0.040 |
Why?
| Continuous Positive Airway Pressure | 1 | 2017 | 58 | 0.040 |
Why?
| Pandemics | 1 | 2022 | 594 | 0.040 |
Why?
| Glycogen | 2 | 2010 | 45 | 0.040 |
Why?
| Caffeine | 1 | 2016 | 77 | 0.030 |
Why?
| Catheterization, Central Venous | 1 | 2017 | 98 | 0.030 |
Why?
| Mice, Inbred C57BL | 1 | 2021 | 2001 | 0.030 |
Why?
| Research Design | 1 | 2017 | 375 | 0.030 |
Why?
| Gastrointestinal Diseases | 1 | 2016 | 134 | 0.030 |
Why?
| Multienzyme Complexes | 2 | 2006 | 41 | 0.030 |
Why?
| Oxidative Stress | 1 | 2020 | 958 | 0.030 |
Why?
| Pregnancy | 1 | 2022 | 2639 | 0.030 |
Why?
| Diagnostic Imaging | 1 | 2016 | 185 | 0.030 |
Why?
| Cardiac Catheterization | 2 | 2009 | 259 | 0.030 |
Why?
| Predictive Value of Tests | 1 | 2017 | 1045 | 0.030 |
Why?
| Postoperative Complications | 1 | 2021 | 1035 | 0.030 |
Why?
| Proportional Hazards Models | 1 | 2015 | 430 | 0.030 |
Why?
| Subcutaneous Fat, Abdominal | 1 | 2013 | 7 | 0.030 |
Why?
| Octreotide | 1 | 2013 | 13 | 0.030 |
Why?
| Intra-Abdominal Fat | 1 | 2013 | 22 | 0.030 |
Why?
| Medicare | 1 | 2015 | 245 | 0.030 |
Why?
| Ubiquitin | 2 | 2003 | 51 | 0.030 |
Why?
| Quality of Health Care | 1 | 2015 | 219 | 0.030 |
Why?
| Health Status Disparities | 1 | 2015 | 219 | 0.030 |
Why?
| Colorado | 1 | 2012 | 15 | 0.030 |
Why?
| Age of Onset | 1 | 2012 | 117 | 0.030 |
Why?
| Rats | 2 | 2010 | 3419 | 0.030 |
Why?
| Acetyl-CoA Carboxylase | 1 | 2010 | 17 | 0.020 |
Why?
| Amino-Acid N-Acetyltransferase | 1 | 2010 | 3 | 0.020 |
Why?
| Sciatic Nerve | 1 | 2010 | 32 | 0.020 |
Why?
| Endothelial Cells | 1 | 2012 | 294 | 0.020 |
Why?
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 314 | 0.020 |
Why?
| Clinical Protocols | 1 | 2010 | 122 | 0.020 |
Why?
| Protein-Energy Malnutrition | 1 | 2009 | 16 | 0.020 |
Why?
| Drug Administration Schedule | 1 | 2010 | 401 | 0.020 |
Why?
| Retrospective Studies | 2 | 2012 | 6459 | 0.020 |
Why?
| Chest Pain | 1 | 2009 | 66 | 0.020 |
Why?
| Cardiac Surgical Procedures | 1 | 2012 | 318 | 0.020 |
Why?
| Down-Regulation | 1 | 2010 | 388 | 0.020 |
Why?
| Longitudinal Studies | 1 | 2011 | 742 | 0.020 |
Why?
| Thermogenesis | 1 | 2008 | 22 | 0.020 |
Why?
| Movement | 1 | 2008 | 111 | 0.020 |
Why?
| Blood Chemical Analysis | 1 | 2007 | 34 | 0.020 |
Why?
| Patient Discharge | 1 | 2010 | 353 | 0.020 |
Why?
| Diglycerides | 1 | 2006 | 12 | 0.020 |
Why?
| Lipolysis | 1 | 2006 | 11 | 0.020 |
Why?
| AMP-Activated Protein Kinases | 1 | 2006 | 29 | 0.020 |
Why?
| Electrocardiography | 1 | 2009 | 290 | 0.020 |
Why?
| Coronary Angiography | 1 | 2009 | 411 | 0.020 |
Why?
| Aerobiosis | 1 | 2006 | 16 | 0.020 |
Why?
| Mitogen-Activated Protein Kinases | 1 | 2006 | 170 | 0.020 |
Why?
| Anticoagulants | 1 | 2009 | 270 | 0.020 |
Why?
| Cohort Studies | 1 | 2010 | 1546 | 0.020 |
Why?
| Hematinics | 1 | 2005 | 18 | 0.020 |
Why?
| Phosphorylation | 1 | 2006 | 613 | 0.020 |
Why?
| Surgical Procedures, Operative | 1 | 2006 | 78 | 0.020 |
Why?
| Drug Utilization | 1 | 2005 | 73 | 0.020 |
Why?
| Glomerular Filtration Rate | 1 | 2005 | 139 | 0.020 |
Why?
| Mice, Inbred ICR | 1 | 2004 | 25 | 0.020 |
Why?
| Erythropoietin | 1 | 2005 | 70 | 0.020 |
Why?
| Gastric Bypass | 1 | 2004 | 22 | 0.020 |
Why?
| Hindlimb Suspension | 1 | 2004 | 45 | 0.020 |
Why?
| Diaphragm | 1 | 2004 | 29 | 0.020 |
Why?
| 3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide) | 1 | 2003 | 6 | 0.020 |
Why?
| Veins | 1 | 2004 | 74 | 0.020 |
Why?
| Bronchiectasis | 1 | 2003 | 10 | 0.010 |
Why?
| Resource Allocation | 1 | 2004 | 19 | 0.010 |
Why?
| Forced Expiratory Volume | 1 | 2003 | 47 | 0.010 |
Why?
| Acidosis | 1 | 2003 | 38 | 0.010 |
Why?
| Extracellular Space | 1 | 2003 | 43 | 0.010 |
Why?
| Immunoglobulin E | 1 | 2003 | 94 | 0.010 |
Why?
| Food Additives | 1 | 2003 | 9 | 0.010 |
Why?
| Caspase 3 | 1 | 2003 | 135 | 0.010 |
Why?
| Complement System Proteins | 1 | 2003 | 56 | 0.010 |
Why?
| Organic Chemicals | 1 | 2003 | 16 | 0.010 |
Why?
| Protein Array Analysis | 1 | 2003 | 28 | 0.010 |
Why?
| Recombinant Proteins | 1 | 2005 | 570 | 0.010 |
Why?
| Graft Survival | 1 | 2004 | 165 | 0.010 |
Why?
| Caspases | 1 | 2003 | 146 | 0.010 |
Why?
| Infant | 1 | 2012 | 3829 | 0.010 |
Why?
| Wound Infection | 1 | 2003 | 31 | 0.010 |
Why?
| Cysteine Endopeptidases | 1 | 2003 | 75 | 0.010 |
Why?
| Comorbidity | 1 | 2004 | 664 | 0.010 |
Why?
| Stroke Volume | 1 | 2003 | 151 | 0.010 |
Why?
| Patient Selection | 1 | 2004 | 284 | 0.010 |
Why?
| Proteasome Endopeptidase Complex | 1 | 2003 | 131 | 0.010 |
Why?
| Norepinephrine | 1 | 2002 | 119 | 0.010 |
Why?
| Recurrence | 1 | 2003 | 692 | 0.010 |
Why?
| Oligonucleotide Array Sequence Analysis | 1 | 2003 | 474 | 0.010 |
Why?
| Combined Modality Therapy | 1 | 2003 | 693 | 0.010 |
Why?
| Incidence | 1 | 2004 | 1083 | 0.010 |
Why?
| Diagnosis, Differential | 1 | 2003 | 1141 | 0.010 |
Why?
| Tomography, X-Ray Computed | 1 | 2003 | 1222 | 0.010 |
Why?
| Gene Expression Profiling | 1 | 2003 | 1141 | 0.010 |
Why?
|
|
Wolfe's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|